Author:
Scherer H. U.,Burmester G. R.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Criscione LG, St Clair EW (2002) Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 14: 204–211
2. Arend WP (2001) Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 45: 101–106
3. Furst DE, Breedveld FC, Kalden JR et al. (2004) Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 63 [Suppl 2]: 112–1112
4. Flendrie M, Creemers MC, Welsing PM, van Riel PL (2004) The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford): 44(4): 472–478
5. Maini RN, Feldmann M (2004) Infliximab therapy. In: Moreland LW, Emery P (eds) Taylor & Francis, London, vol 2, pp 23–45
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献